Centessa clears HSR antitrust review for Eli Lilly acquisition; shareholder vote pending

Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• high

  The Hart-Scott-Rodino Act waiting period expired May 21, removing the key U.S. antitrust hurdle for Eli Lilly's acquisition of Centessa announced March 31, 2026.

  Item 8.01 verify on EDGAR →
• high

  Deal closing still requires Centessa shareholder approval and UK High Court sanction of the scheme of arrangement—standard conditions for UK-based acquisitions that remain outstanding.

  Item 8.01 verify on EDGAR →
• medium

  Centessa filed its definitive proxy statement May 7 and mailed it to shareholders, providing voting materials and transaction details required under SEC and UK law.

  Item 8.01 verify on EDGAR →